ByTrending Posts
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New…
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment…
Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model…
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention…
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic…
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in…
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital…
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio…
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could GE HealthCare’s FDA-Cleared Revolution™ Vibe CT System…
Key Highlights Revolutionizing Cardiac Imaging with One-Beat ClarityGE HealthCare’s Revolution Vibe CT system has received U.S. FDA 510(k)…
Trending Posts
Latest Stories
Is Strategic Out-Licensing the Fastest Path to Global Scale? Restari Secures $230 Million PDE-5 Deal with AriBio
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for…
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused…
Is AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a Paradigm Shift in Pharma R&D
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global…
Gallery
